Smith & Nephew Share Forecast, Price & News

GBX 1,328.50
-22.50 (-1.67 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.57 million shs
Average Volume343,671 shs
Market Capitalization£11.68 billion
P/E Ratio29.20
Dividend Yield2.01%
30 days | 90 days | 365 days | Advanced Chart
Receive SN News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

Smith & Nephew logo

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.15 out of 5 stars

Analyst Opinion: 3.3Community Rank: 4.1Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Smith & Nephew (LON:SN) Frequently Asked Questions

Is Smith & Nephew a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Smith & Nephew stock.
View analyst ratings for Smith & Nephew
or view top-rated stocks.

What stocks does MarketBeat like better than Smith & Nephew?

Wall Street analysts have given Smith & Nephew a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Smith & Nephew wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Smith & Nephew's stock price been impacted by COVID-19?

Smith & Nephew's stock was trading at GBX 1,506 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SN stock has decreased by 11.8% and is now trading at GBX 1,328.50.
View which stocks have been most impacted by COVID-19

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew announced a dividend on Thursday, July 29th. Investors of record on Thursday, September 30th will be given a dividend of GBX 0.14 per share on Wednesday, October 27th. This represents a yield of 0.71%. The ex-dividend date of this dividend is Thursday, September 30th. The official announcement can be seen at this link.
View Smith & Nephew's dividend history

Is Smith & Nephew a good dividend stock?

Smith & Nephew pays an annual dividend of GBX 27 per share and currently has a dividend yield of 2.01%. The dividend payout ratio of Smith & Nephew is 59.34%. This payout ratio is at a healthy, sustainable level, below 75%.
View Smith & Nephew's dividend history.

What price target have analysts set for SN?

5 Wall Street analysts have issued twelve-month price objectives for Smith & Nephew's shares. Their forecasts range from GBX 1,579 to GBX 2,020. On average, they anticipate Smith & Nephew's share price to reach GBX 1,801 in the next year. This suggests a possible upside of 35.6% from the stock's current price.
View analysts' price targets for Smith & Nephew
or view top-rated stocks among Wall Street analysts.

Who are Smith & Nephew's key executives?

Smith & Nephew's management team includes the following people:
  • Mr. Roland D. Diggelmann, CEO & Director (Age 54, Pay $1.7M)
  • Ms. Anne-Francoise Nesmes, CFO & Exec. Director (Age 49, Pay $799.64k)
  • Mr. Mark Gladwell, Pres of Global Operations & Global Bus. Services (Age 46)
  • Mr. Andrew Swift, VP of Investor Relations
  • Ms. Catheryn O'Rourke, Chief Legal & Compliance Officer (Age 48)
  • Mr. Joe Metzger, Sr. VP of Marketing Services & Communications
  • Ms. Elga Lohler, Chief HR Officer (Age 53)
  • Mr. Philip G. Cowdy, Chief Bus. Devel. & Corp. Affairs Officer (Age 54)
  • Mr. Bradley Cannon, Pres of Sports Medicine & ENT (Age 53)
  • Dr. Vasant Padmanabhan, Pres of R&D (Age 54)

Who are some of Smith & Nephew's key competitors?

What other stocks do shareholders of Smith & Nephew own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Imperial Brands (IMB), Smith & Nephew (SNN), Alexion Pharmaceuticals (ALXN), Barclays (BARC), GlaxoSmithKline (GSK), Diageo (DGE), Standard Chartered (STAN), Unilever (ULVR), British American Tobacco (BATS) and BHP Group (BHP).

What is Smith & Nephew's stock symbol?

Smith & Nephew trades on the London Stock Exchange (LON) under the ticker symbol "SN."

How do I buy shares of Smith & Nephew?

Shares of SN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Smith & Nephew's stock price today?

One share of SN stock can currently be purchased for approximately GBX 1,328.50.

How much money does Smith & Nephew make?

Smith & Nephew has a market capitalization of £11.68 billion and generates £5.12 billion in revenue each year.

How many employees does Smith & Nephew have?

Smith & Nephew employs 312 workers across the globe.

What is Smith & Nephew's official website?

The official website for Smith & Nephew is www.smith-nephew.com.

Where are Smith & Nephew's headquarters?

Smith & Nephew is headquartered at 15 Adam Street, LONDON, WC2N 6LA, United Kingdom.

How can I contact Smith & Nephew?

Smith & Nephew's mailing address is 15 Adam Street, LONDON, WC2N 6LA, United Kingdom. The company can be reached via phone at +44-20-74017646.

This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.